

**[PDF] Relapsed or refractory classical Hodgkin lymphoma: ...**

[https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045\(21\)00138-8.pdf](https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(21)00138-8.pdf)

relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. Br J Haematol. 2017; 179: 471-79. 7 Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the...

**Therapeutic Updates for Relapsed and Refractory Classical ...**

<https://www.mdpi.com/2072-6694/12/10/2887/htm>

Hodgkin lymphoma (HL) is a B-cell malignancy representing approximately one in ten lymphomas diagnosed in the United States annually. The majority of patients with HL can be cured with...

Cited by: 1 Author: Timothy J Voorhees, Anne W Beaven  
Publish Year: 2020

PEOPLE ALSO ASK

Is there a cure for Hodgkin's lymphoma? ▾

How is sintilimab used to treat classical Hodgkin lymphoma? ▾

When was radiation therapy first used to treat Hodgkin ' s lymphoma? ▾

What are the current advances in Hodgkin ' s lymphoma? ▾

Feedback

**Optimizing outcomes in relapsed/refractory Hodgkin ...**

<https://journals.sagepub.com/doi/full/10.1177/2040620720902911>

Feb 16, 2020 · Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haemat...

Cited by: 1 Author: Theodoros P Vassilakopoulos, John V As...  
Publish Year: 2020

**(PDF) Optimizing outcomes in relapsed/refractory Hodgkin ...**

<https://www.researchgate.net/publication/339308707...>

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-ChL) has improved

**Therapeutic Updates for Relapsed and Refractory Classical ...**<https://www.mdpi.com/2072-6694/12/10/2887/htm>

**Hodgkin lymphoma** (HL) is a B-cell malignancy representing approximately one in ten lymphomas diagnosed in the United States annually. The majority of patients with HL can be cured with...

Cited by: 2 Author: Timothy J Voorhees, Anne W Beaven  
Publish Year: 2020

**(PDF) Optimizing outcomes in relapsed/refractory Hodgkin ...**<https://www.researchgate.net/publication/339308707...>

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has improved considerably in recent years owing to the approval of highly active novel agents such as ...

**Optimizing outcomes in relapsed/refractory Hodgkin ...**<https://journals.sagepub.com/doi/10.1177/2040620720902911>

Feb 16, 2020 · Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol...

Cited by: 3 Author: Theodoros P Vassilakopoulos, John V Asi...  
Publish Year: 2020

**Improved clinical outcome in a randomized phase II study ...**<https://europepmc.org/article/PMC/PMC8025784>

Apr 01, 2021 · Programmed death-1 (PD-1) blockade therapy has been approved and recommended for both the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progresse...

**Addition of Low-Dose Decitabine to Anti-PD-1 Antibody ...**<https://www.researchgate.net/publication/332769821...>

(43) A combination of DAC plus anti-PD-1 camrelizumab gave a better complete remission rate than camrelizumab alone in patients with relapsed/refractory Hodgkin's lymphoma. (44) Low-dose DAC ...

**[PDF] Improved outcomes of high-risk relapsed Hodgkin lymphoma ...**<https://haematologica.org/article/download/haematol.2021.278311/73353>

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a ...

**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 64483

**Manuscript Type:** CASE REPORT

**Relapsed/refractory classical Hodgkin lymphoma effectively treated by combination low-dose decitabine plus tislelizumab: A case report**

Ding XS *et al.* Decitabine plus tislelizumab in Hodgkin lymphoma

Xiao-Sheng Ding, Lan Mi, Yu-Qin Song, Wei-Ping Liu, Hui Yu, Ning-Jing Lin, Jun Zhu

#### Abstract

##### BACKGROUND

Academic studies proved that anti-programmed death-1 (PD-1) monoclonal antibodies demonstrated remarkable activity in relapsed/refractory classical Hodgkin lymphoma (cHL). However, most patients ultimately experienced failure or resistance. It is urgent and necessary to develop novel strategy for relapsed/refractory cHL. The aim of the

#### Match Overview

Match	Source	Words	Similarity
1	Internet crawled on 27-Nov-2019 ascopubs.org	61 words	3%
2	Internet crawled on 24-Jul-2020 www.sagepub.com	56 words	3%
3	Internet www.ncbi.nlm.nih.gov	31 words	2%
4	Crossref "Report from the virtual American Society of Hematology ... (ASH) Annual Meeting, December 5th–6th, 2020", memo	29 words	1%
5	Crossref Hassan E. Ghoneim, Yiping Fan, Ardiana Moustaki, Hosam A. Abdelsamed et al. "De Novo Epigenetic Programs ...	27 words	1%
6	Internet crawled on 15-Apr-2016 hematol.jco.ascopubs.org	19 words	1%
7	Internet crawled on 26-Oct-2020 www.nature.com	16 words	1%
8	Internet crawled on 19-Aug-2014 ijcm.org	15 words	1%
9	Crossref Yuchen Liu, Renhong Huang, Liantang Liu, Yanchun Meng, Xiaojian Liu. "Epigenetic abnormalities of classical H... www.wjg.com	14 words	1%

国内版 国际版

Relapsed/refractory classical Hodgkin lymphoma effectively treated



ALL IMAGES VIDEOS

14,000 Results Any time ▾

### Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in ...

<https://clincancerres.aacrjournals.org/content/27/10/2782> ▾

Purpose: Programmed death-1 (PD-1) blockade monotherapy is effective in relapsed/refractory classical Hodgkin lymphoma (cHL), but a subset of patients is recalcitrant to PD-1 inhibitors and onl...

### Therapeutic Updates for Relapsed and Refractory Classical ...

<https://www.mdpi.com/2072-6694/12/10/2887/htm> ▾

The approach to relapsed and refractory classical Hodgkin lymphoma is rapidly evolving. Over the past five years, we have seen the arrival of novel immunotherapies with impressive clinical response rat...

Cited by: 2 Author: Timothy J Voorhees, Anne W Beaven

Publish Year: 2020 Estimated Reading Time: 8 mins

### Optimizing outcomes in relapsed/refractory Hodgkin ...

<https://journals.sagepub.com/doi/full/10.1177/2040620720902911>

Feb 16, 2020 · The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (r-cHL) has improved considerably in recent years owing to the approval of highly active novel agents suc...

Cited by: 3 Author: Theodoros P Vassilakopoulos, John V As...

Publish Year: 2020 Estimated Reading Time: 4 mins

### Improved clinical outcome in a randomized phase II study ...

<https://europepmc.org/article/PMC/PMC8025784> ▾

Apr 01, 2021 · Thus, decitabine-plus-camrelizumab combination may be an extremely effective regimen for patients with relapsed/refractory cHL who progressed/relapsed after ASCT, especially if...

### (PDF) Improved clinical outcome in a randomized phase II ...

<https://www.researchgate.net/publication/350645191...>

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma April 2021 Journal for ImmunoTherapy of Cancer 9(4):e002347

### Addition of Low-Dose Decitabine to Anti-PD-1 Antibody ...

<https://www.researchgate.net/publication/332769821...>

(43) A combination of DAC plus anti-PD-1 camrelizumab gave a better complete remission rate than